[1]
American Psychiatric Association. Diagnostic and statistical manual of mental disorders; 5th ed; (DSM-5): Arlington, VA, 2013.
[2]
Weisman, M.M.; Bland, R.C.; Canino, G.J.; Greenwald, S.; Hwu, H.G.; Lee, C.K.; Wittchen, H.U. The cross-national epidemiology of obsessive-compulsive disorder. J. Clin. Psychiatry, 1994, 55, 5-10.
[3]
Eichstedt, J.A.; Arnold, S.L. Childhood-onset obsessive-compulsive disorder: A tic-related subtype of OCD? Clin. Psychol. Rev., 2001, 21(1), 137-157. [http://dx.doi.org/10.1016/S0272-7358(99)00044-6]. [PMID: 11148894].
[4]
Geller, P.A.; Klier, C.M.; Neugebauer, R. Anxiety disorders following miscarriage. J. Clin. Psychiatry, 2001, 62(6), 432-438. [http://dx.doi.org/10.4088/JCP.v62n0606]. [PMID: 11465520].
[5]
Saxena, S.; Bota, R.G.; Brody, A.L. Brain-behavior relationships in obsessive-compulsive disorder. Semin. Clin. Neuropsychiatry, 2001, 6(2), 82-101. [http://dx.doi.org/10.1053/scnp.2001.21833]. [PMID: 11296309].
[6]
Scarone, S.; Colombo, C.; Livian, S.; Abbruzzese, M.; Ronchi, P.; Locatelli, M.; Smeraldi, E. Increased right caudate nucleus size in obsessive-compulsive disorder: detection with magnetic resonance imaging. Psychiatry Res. Neuroimaging, 1992, 45, 115-121. [http://dx.doi.org/10.1016/0925-4927(92)90005-O].
[7]
Robinson, D.; Wu, H.; Munne, R.A.; Ashtari, M.; Alvir, J.M.; Lerner, G.; Koreen, A.; Cole, K.; Bogerts, B. Reduced caudate nucleus volume in obsessive-compulsive disorder. Arch. Gen. Psychiatry, 1995, 52(5), 393-398. [http://dx.doi.org/10.1001/archpsyc. 1995.03950170067009]. [PMID: 7726720].
[8]
Szeszko, P.R.; Robinson, D.; Alvir, J.M.; Bilder, R.M.; Lencz, T.; Ashtari, M.; Wu, H.; Bogerts, B. Orbital frontal and amygdala volume reductions in obsessive-compulsive disorder. Arch. Gen. Psychiatry, 1999, 56(10), 913-919. [http://dx.doi.org/10.1001/archpsyc. 56.10.913]. [PMID: 10530633].
[9]
Khalsa, S.S.; Schiffman, J.E.; Bystritsky, A. Treatment-resistant OCD: options beyond first-line medications. Curr. Psychiatr., 2011, 10, 45.
[10]
Ninan, P.T.; Koran, L.M.; Kiev, A. High-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive disorder: A multicenter double-blind trial. Year Book of Psychiatry & Applied Mental Health, 2007, 2007, 242-243. [http://dx.doi. org/10.1016/S0084-3970(08)70541-3].
[11]
Dell’osso, B.; Mundo, E.; Marazziti, D.; Altamura, A.C. Switching from serotonin reuptake inhibitors to duloxetine in patients with resistant obsessive compulsive disorder: a case series. J. Psychopharmacol. (Oxford), 2008, 22(2), 210-213. [http://dx.doi.org/ 10.1177/0269881107079865]. [PMID: 18208931].
[12]
Pallanti, S.; Quercioli, L.; Paiva, R.S.; Koran, L.M. Citalopram for treatment-resistant obsessive-compulsive disorder. Eur. Psychiatry, 1999, 14(2), 101-106. [http://dx.doi.org/10.1016/S0924-9338(99) 80725-1]. [PMID: 10572334].
[13]
Ravizza, L.; Barzega, G.; Bellino, S.; Bogetto, F.; Maina, G. Therapeutic effect and safety of adjunctive risperidone in refractory obsessive-compulsive disorder (OCD). Psychopharmacol. Bull., 1996, 32(4), 677-682. [PMID: 8993091].
[14]
Fallon, B.A.; Liebowitz, M.R.; Campeas, R. Intravenous clomipramine for obsessive-compulsive disorder refractory to oral clomipramine: A placebo-controlled study. Year Book of Psychiatry and Applied Mental Health, 2000, 2000, 345-346.
[15]
Dannon, P.N.; Sasson, Y.; Hirschmann, S.; Iancu, I.; Grunhaus, L.J.; Zohar, J. Pindolol augmentation in treatment-resistant obsessive compulsive disorder: a double-blind placebo controlled trial. Eur. Neuropsychopharmacol., 2000, 10(3), 165-169. [http://dx. doi.org/10.1016/S0924-977X(00)00065-1]. [PMID: 10793318].
[16]
Hewlett, W.A.; Schmid, S.P.; Salomon, R.M. Pilot trial of ondansetron in the treatment of 8 patients with obsessive-compulsive disorder. J. Clin. Psychiatry, 2003, 64(9), 1025-1030. [http://dx.doi.org/ 10.4088/JCP.v64n0907]. [PMID: 14628977].
[17]
Saxena, S.; Brody, A.L.; Maidment, K.M.; Dunkin, J.J.; Colgan, M.; Alborzian, S.; Phelps, M.E.; Baxter, L.R., Jr Localized orbitofrontal and subcortical metabolic changes and predictors of response to paroxetine treatment in obsessive-compulsive disorder. Neuropsychopharmacology, 1999, 21(6), 683-693. [http://dx. doi.org/10.1016/S0893-133X(99)00082-2]. [PMID: 10633474].
[18]
Atmaca, M.; Yildirim, H.; Ozdemir, H.; Tezcan, E.; Poyraz, A.K. Volumetric MRI study of key brain regions implicated in obsessive-compulsive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2007, 31(1), 46-52. [http://dx.doi.org/10.1016/j.pnpbp. 2006.06.008]. [PMID: 16859819].
[19]
Gilbert, A.R.; Moore, G.J.; Keshavan, M.S.; Paulson, L.A.; Narula, V.; Mac Master, F.P.; Stewart, C.M.; Rosenberg, D.R. Decrease in thalamic volumes of pediatric patients with obsessive-compulsive disorder who are taking paroxetine. Arch. Gen. Psychiatry, 2000, 57(5), 449-456. [http://dx.doi.org/10.1001/archpsyc.57.5.449]. [PMID: 10807485].
[20]
Hoexter, M.Q.; de Souza Duran, F.L.; D’Alcante, C.C.; Dougherty, D.D.; Shavitt, R.G.; Lopes, A.C.; Diniz, J.B.; Deckersbach, T.; Batistuzzo, M.C.; Bressan, R.A.; Miguel, E.C.; Busatto, G.F. Gray matter volumes in obsessive-compulsive disorder before and after fluoxetine or cognitive-behavior therapy: a randomized clinical trial. Neuropsychopharmacology, 2012, 37(3), 734-745. [http://dx. doi.org/10.1038/npp.2011.250]. [PMID: 22030709].
[21]
Lázaro, L.; Bargalló, N.; Castro-Fornieles, J.; Falcón, C.; Andrés, S.; Calvo, R.; Junqué, C. Brain changes in children and adolescents with obsessive-compulsive disorder before and after treatment: a voxel-based morphometric MRI study. Psychiatry Res., 2009, 172(2), 140-146. [http://dx.doi.org/10.1016/j.pscychresns.2008.12. 007]. [PMID: 19321314].
[22]
Atmaca, M.; Mermi, O.; Yildirim, H.; Gurok, M.G. Orbito-frontal cortex and thalamus volumes in obsessive-compulsive disorder before and after pharmacotherapy. Brain Imaging Behav., 2016, 10(3), 669-674. [http://dx.doi.org/10.1007/s11682-015-9426-0]. [PMID: 26311393].
[23]
Atmaca, M.; Yildirim, H.; Mermi, O.; Gurok, M.G. Effects of anti-obsessional treatment on pituitary volumes in obsessive-compulsive disorder. Psychiatr. Danub., 2016, 28(1), 58-62. [PMID: 26938823].
[24]
Yun, J.Y.; Jang, J.H.; Kim, S.N.; Jung, W.H.; Kwon, J.S. Neural correlates of response to pharmacotherapy in obsessive-compulsive disorder: Individualized cortical morphology-based structural covariance. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2015, 63(63), 126-133. [http://dx.doi.org/10.1016/j.pnpbp.2015.06.009]. [PMID: 26116795].
[25]
Björgvinsson, T.; Hart, J.; Heffelfinger, S. Obsessive-compulsive disorder: update on assessment and treatment. J. Psychiatr. Pract., 2007, 13(6), 362-372. [http://dx.doi.org/10.1097/01.pra.0000300122. 76322.ad]. [PMID: 18032981].
[26]
Brem, S.; Hauser, T.U.; Iannaccone, R.; Brandeis, D.; Drechsler, R.; Walitza, S. Neuroimaging of cognitive brain function in paediatric obsessive compulsive disorder: A review of literature and preliminary meta-analysis. J. Neural Transm. (Vienna), 2012, 119(11), 1425-1448. [http://dx.doi.org/10.1007/s00702-012-0813-z]. [PMID: 22678698].
[27]
Chamberlain, S.R.; Menzies, L.; Hampshire, A.; Suckling, J.; Fineberg, N.A.; del Campo, N.; Aitken, M.; Craig, K.; Owen, A.M.; Bullmore, E.T.; Robbins, T.W.; Sahakian, B.J. Orbitofrontal dysfunction in patients with obsessive-compulsive disorder and their unaffected relatives. Science, 2008, 321(5887), 421-422. [http://dx.doi.org/10.1126/science.1154433]. [PMID: 18635808].
[28]
Rotge, J.Y.; Guehl, D.; Dilharreguy, B.; Cuny, E.; Tignol, J.; Bioulac, B.; Allard, M.; Burbaud, P.; Aouizerate, B. Provocation of obsessive-compulsive symptoms: A quantitative voxel-based meta-analysis of functional neuroimaging studies. J. Psychiatry Neurosci., 2008, 33(5), 405-412. [PMID: 18787662].
[29]
Menzies, L.; Chamberlain, S.R.; Laird, A.R.; Thelen, S.M.; Sahakian, B.J.; Bullmore, E.T. Integrating evidence from neuroimaging and neuropsychological studies of obsessive-compulsive disorder: the orbitofronto-striatal model revisited. Neurosci. Biobehav. Rev., 2008, 32(3), 525-549. [http://dx.doi.org/10.1016/j.neubiorev. 2007.09.005]. [PMID: 18061263].
[30]
Bhikram, T.P.; Farb, N.A.S.; Ravindran, L.N.; Papadopoulos, Y.G.; Conn, D.K.; Pollock, B.G.; Ravindran, A.V. The effect of intravenous citalopram on the neural substrates of obsessive-compulsive disorder. J. Neuropsychiatry Clin. Neurosci., 2016, 28(3), 243-247. [http://dx.doi.org/10.1176/appi.neuropsych.15090213]. [PMID: 27019066].
[31]
Jang, J.H.; Kwon, J.S.; Jang, D.P.; Moon, W.J.; Lee, J.M.; Ha, T.H.; Chung, E.C.; Kim, I.Y.; Kim, S.I. A proton MRSI study of brain N-acetylaspartate level after 12 weeks of citalopram treatment in drug-naive patients with obsessive-compulsive disorder. Am. J. Psychiatry, 2006, 163(7), 1202-1207. [http://dx.doi.org/ 10.1176/ajp.2006.163.7.1202]. [PMID: 16816225].
[32]
Han, J.Y.; Kang, D.H.; Gu, B.M.; Jung, W.H.; Choi, J.S.; Choi, C.H.; Jang, J.H.; Kwon, J.S. Altered brain activation in ventral frontal-striatal regions following a 16-week pharmacotherapy in unmedicated obsessive-compulsive disorder. J. Korean Med. Sci., 2011, 26(5), 665-674. [http://dx.doi.org/10.3346/jkms.2011.26.5. 665]. [PMID: 21532859].
[33]
Yoo, S.Y.; Jang, J.H.; Shin, Y.W.; Kim, D.J.; Park, H.J.; Moon, W.J.; Chung, E.C.; Lee, J.M.; Kim, I.Y.; Kim, S.I.; Kwon, J.S. White matter abnormalities in drug-naïve patients with obsessive-compulsive disorder: a diffusion tensor study before and after citalopram treatment. Acta Psychiatr. Scand., 2007, 116(3), 211-219. [http://dx.doi.org/10.1111/j.1600-0447.2007.01046.x]. [PMID: 17655563].
[34]
Kamini, L. Ho, Piana.; Harold, J.G.M.; van, Megen.; Nick, F. Ramsey.; Rene, Mandla.; Peter P, van Rijkb.; Wynne H.J.; Herman, G.M.; Westenberga, T. Decreased thalamic blood flow in obsessive-compulsive disorder patients responding to fluvoxamine. Psychiatry Res. Neuroimaging, 2005, 138, 89-97. [http://dx.doi.org/ 10.1016/j.pscychresns.2004.12.003].
[35]
Ho Pian, K.L.; van Megen, H.J.; Ramsey, N.F.; Mandl, R.; van Rijk, P.P.; Wynne, H.J.; Westenberg, H.G. Decreased thalamic blood flow in obsessive-compulsive disorder patients responding to fluvoxamine. Psychiatry Res., 2005, 138(2), 89-97. [http://dx.doi. org/10.1016/j.pscychresns.2004.12.003]. [PMID: 15766633].
[36]
Wen, S.L.; Cheng, M.H.; Cheng, M.F.; Yue, J.H.; Wang, H. Pharmacotherapy response and regional cerebral blood flow characteristics in patients with obsessive-compulsive disorder. Behav. Brain Funct., 2013, 30, 9-31. [http://dx.doi.org/10.1186/1744-9081-9-31].
[37]
Shin, D.J.; Jung, W.H.; He, Y.; Wang, J.; Shim, G.; Byun, M.S.; Jang, J.H.; Kim, S.N.; Lee, T.Y.; Park, H.Y.; Kwon, J.S. The effects of pharmacological treatment on functional brain connectome in obsessive-compulsive disorder. Biol. Psychiatry, 2014, 75(8), 606-614. [http://dx.doi.org/10.1016/j.biopsych.2013.09.002]. [PMID: 24099506].
